Can a gentler drug trio tame small cell lung cancer in older patients?
NCT ID NCT07728955
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial is testing a combination of three drugs—benmelstobart, anlotinib, and etoposide—as a first treatment for elderly patients (65 and older) or those too frail for standard intensive chemotherapy. The goal is to see if this platinum-free regimen can control the cancer and extend time without progression. Participants will receive the drugs for several cycles, then continue on two of them as maintenance therapy until the disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of benmelstobart, anlotinib, and etoposide
- What this could lead to
- If it works, this could offer a gentler, effective first-line treatment option for elderly or frail patients with small cell lung cancer who cannot tolerate standard intensive chemotherapy.
- What could go wrong
- This is a small, single-arm trial without a comparison group, so results may not be definitive. The drug combination may still cause significant side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at stubborn lung cancer
- Could a hidden nerve condition be more common in lung cancer than we think?
- Experimental combo aims to tackle Treatment-Resistant cancers
- New PET scan targets hidden lung cancer cells
- New drug THE-0504 enters human testing for tough cancers
- Gene therapy safety check: 400 cancer patients monitored for years